Patients and Methods
In a phase 2 study (NCT01728233), patients received dacomitinib 45 mg/day, orally, continuously. Inclusion criteria were SCC histology, clinical stage N 2-3 or M 1 (Tumour-Node-Metastasis classification system 2009), and no prior chemotherapy administration. The primary endpoint was the objective response rate (ORR, according to the Response Evaluation Criteria in Solid Tumors, version 1.1). Stopping rules based on the Bayesian posterior probability (PP) to demonstrate that the ORR exceeded 20% were set.
Results
From June 2013 to October 2016, 28 patients were treated. Eight (28.6%) had visceral metastases, 14 (50%) had pelvic and 17 (60.7%) clinically involved bilateral lymph nodes. One complete and eight partial responses were obtained (ORR 32.1%, 80% credibility interval 21.0-43.0%). The median (interquartile range [IQR] ) follow-up duration was 19.8 (6.3-25.7) months; 12-month progression-free survival was 26.2% (95% confidence interval [CI] 13.2-51.9); 12-month overall survival (OS) was 54.9% (95% CI 36. 4-82.8) . The median (IQR) OS of locally advanced patients was 20 (11.1-not reached) months. The Bayesian PP of exceeding the 20% ORR target was 92.3%. Grade 3 adverse events (skin rash) were seen in three patients (10.7%). Tissue samples from 25 patients were analysed. Only two patients had high-risk human papillomavirus-positive tumours. Epidermal growth factor receptor (EGFR) amplification was found in four patients (equally responders and non-responders) and it was confirmed in all post-dacomitinib samples. Telomerase reverse transcriptase (TERT) mutations were found in responders only (60%), and phosphatidylinositol 3-kinase/ mammalian target of rapamycin (PI3K/mTOR) pathway gene mutations were found in 42.9% of responders vs 8.3% of non-responders.
Introduction
Patients with disseminated clinical involvement of inguinal or pelvic lymph nodes from penile squamous cell carcinoma (PSCC) have a poor prognosis despite adequate treatment. Surgery, the mainstay of treatment, is insufficient as a standalone option and multimodal approaches are recommended for these patients [1] [2] [3] . In particular, the administration of neoadjuvant chemotherapy consisting of a cisplatin and taxane-based regimen is recommended in patients presenting with bulky or fixed inguinal lymph nodes, or with enlarged pelvic lymph nodes [2, 3] . However, such chemotherapy regimens exert moderate antitumour activity and long-term outcomes are dismal. Evidence from the literature is based on a USA single-arm, phase 2 study of paclitaxel, ifosfamide and cisplatin (TIP), whereby an objective response-rate (ORR) of 50% in 30 patients was obtained, as well as on a few European trials and retrospective studies of docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy [4] [5] [6] [7] . Overall, results that can be achieved with perioperative chemotherapy in patients with locally advanced PSCC with clinical lymph node involvement have been retrospectively analysed. Patients who received neoadjuvant chemotherapy showed a 53.2% ORR and achieved a pathological complete response in 13.8% of cases. However, their median progression-free (PFS) and overall survival (OS) were 7.7 and 17.1 months, respectively [8] . Also, tolerability of platinumbased combined chemotherapy is suboptimal in this patient population, usually represented by frail patients with comorbidities. In patients with distant metastatic disease no effective therapy exists. Prognostic factors and survival in these patients have also been evaluated retrospectively [9] .
Amongst the most suitable therapeutic targets in PSCC, human epidermal growth factor receptor (HER) family genes, namely EGFR, did represent the objective of studies of firstgeneration anti-EGFR compounds, and a few case reports and small case series have been reported [10] [11] [12] . In our hypothesis, new more potent, irreversible, pan-HER tyrosine kinase inhibitors (TKIs) may improve the results that can be achieved with these compounds, and provide better tolerability compared to chemotherapy. Dacomitinib (Pfizer Oncology, New York, NY, USA) is a potent, highly selective, orally administered, small molecule, irreversible TKI of EGFR, ERBB2, HER2, and ERBB4 [13] [14] [15] [16] [17] .
Patients and Methods

Study Design and Patient Population
Her-Uro-01 was an open-label, single-centre, single-arm, phase 2 study. Key eligibility criteria included the following: histologically confirmed diagnosis of PSCC, Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) 0-1, and clinical stage N 2-3 and/or M 1 (according to the TNM 2009 classification system [18] ). Prior chemotherapy administration was not allowed, whereas relapsing disease after previous lymph node dissection (LND) was allowed. Tru-cut biopsy of enlarged inguinal lymph nodes was optionally proposed to the patients during the screening period. The protocol was approved by the independent ethics committee of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (the study sponsor). The trial is registered with ClinicalTrials.gov (ID number: NCT01728233).
Study Procedures
Patients were orally administered 45 mg of dacomitinib once daily until evidence of disease progression or onset of unacceptable toxicity appeared. During the screening phase, complete blood and urine tests were conducted. The treatment response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [19] via triphasic contrast-enhanced, thoraxabdomen CT every 8 weeks. CT scans were matched with whole-body 18 F-fluorodeoxyglucose positron-emission tomography ( 18 FDG-PET)/CT scans each time. All scans were performed at our centre, and RECIST responses were assessed by a reference radiologist (G.C.). Definition of response based on changes in FDG avidity relied on the European Organisation for Research and Treatment of Cancer (EORTC) criteria [20] . Adverse events (AEs) were graded according to the National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.03. At the time of tumour response assessment, every patient was discussed in a multidisciplinary clinic and surgery (i.e., inguinal lymphadenectomy, with or without pelvic LND, according to the institutional standard [21] ) was offered to responding patients. Post-surgical management relied on our standard practice [7, 22] .
Planned Translational Analyses of Tumour Samples
For pre-and post-dacomitinib tumour samples the following analyses were planned: EGFR and ERBB2 amplification on formalin-fixed, paraffin-embedded (FFPE) tissue sections, high-risk human papillomavirus (HR-HPV) status, and nextgeneration sequencing (NGS).
Fluorescence in situ hybridisation (FISH) analysis was performed using a commercially available, specific probe (Vysis LSI EGFR Spectrum Orange/CEP7 Spectrum Green Probe, Abbott Molecular Inc., Des Plaines, IL, USA) to detect the amplification of EGFR gene, defined as previously described [23] , ERBB2 gene status was assessed by bright field dual-colour silver ISH (SISH) analysis (INFORM HER2 Dual ISH DNA Probe; Ventana Medical Systems, Tucson, AZ, USA) on a BenchMark Ultra Platform (Ventana Medical Systems) according to the manufacturer's protocol. HPV infection was assessed according to a previously described algorithm that relies on p16 immunohistochemistry and HR-HPV DNA ISH [24] . To definitively ascertain the HPV status, E6/E7 mRNA ISH assay was used in p16 positive/HR-HPV DNA-negative samples. Finally, molecular characterisation was performed via NGS. DNA was extracted from FFPE tumour tissues using the GeneRead DNA FFPE Kit TM (Qiagen, Hilden, Germany). DNA was then profiled using a custom gene panel (i.e., 'HotSpot' panel, Life Technologies, Carlsbad, CA, USA), which targets the coding sequences of 50 tumour suppressor genes and oncogenes frequently mutated in human cancers, the Ion AmpliSeq Library Kit2.0 TM , and the Ion Torrent Personal Genome Machine TM platform (Life Technologies). In a subgroup of patients, a broader custom panel of 111 genes (i.e., 'magic' panel) was used (Fig. S1 ). Sanger sequencing was performed to validate representative NGS calls, as well as to explore ERBB3 mutations that were not covered in the above panels.
Statistical Analyses
The study was originally planned according to Simon's optimal two-stage design with the aim of demonstrating an increase in the ORR from 5% to a desirable 20%. Accordingly, the threshold for rejecting the null hypothesis and to favourably judge the activity of the experimental treatment required four objective responses out of the total 37 patients with a one-sided 10% significance level and 90% power. Over the study, the target number of responses was achieved well in advance of recruitment completion. With such a positive outcome, rather than curtailing the study, we amended the trial by introducing a stronger evidence criterion. In particular, we sought to demonstrate an ORR of >20% based on calculation of the Bayesian posterior probability, and a 90% threshold for such a probability was adopted as a stopping rule. Calculations were done relying on the b distribution and corresponding prior parameters were set to a 0 = 0.2 and b 0 = 0.8. Univariable logistic and Cox proportional hazard regression models were generated. The results were considered statistically significant whenever a two-sided P < 0.05 was achieved. The analyses were conducted using the Statistical Analysis System (SAS â , SAS Institute Inc., Cary, NC, USA) and R software (http://www.rproject.org/, last accessed 15 January 2017).
Results
Baseline Patient and Disease Characteristics
Analyses were based on 12 December 2016 cut-off date. Between June 2013 and October 2016, 28 patients were enrolled in the study. The details of the study population are provided in Table 1 . In particular, there were 20 patients with locally advanced disease (i.e., inguinal lymph node involvement, with or without enlarged pelvic lymph nodes, unilateral or bilateral), whereas eight patients had visceral metastatic disease. Notably, 11 patients (39.3%) had already received at least one LND, consisting of inguinal LND in five cases and inguinal-pelvic LND in six, and presented with a locoregional relapse.
Response, Survival Outcomes and Safety Results
Intention-to-treat analysis was applied. A decrease in target lesions from baseline was seen in 17 patients (60.7%), including one complete response (3.6%) and eight partial responses (28.6%): the ORR was 32.1% (80% credibility interval: 21.0-43.0%). Additionally, 13 patients (46.4%) had stable disease, and six patients had progressive disease (21.4%). One case with stable disease of the skin nodules was enrolled and included in intention-to-treat analyses, and another case had clinically confirmed disease progression (Table 2 and Fig. 1 ). Eighteen patients (72%) had a PETpartial response. The Bayesian posterior probability of exceeding the 20% ORR target was 92.3%. The median (interquartile range [IQR]) follow-up duration was 19.8 (6.3-25.7) months. The 12-month PFS probability was 26.2% (95% CI 13.2-51.9%), and the median (IQR) PFS duration was 4.1 (3.1-not reached) months (Table 2 and Fig. 2A ). The 12-month OS probability was 54.9% (95% CI 36.4-82.8%), and the median (IQR) OS duration was 13.7 (9.9-not reached) months (Fig. 2B) . Results in the subgroup of patients according to disease extension are also shown in Table 2 and in Fig. 2C,D ; notably, the median OS in patients with locally advanced disease was 20 months (95% CI 11.1-not reached). Univariable analyses did not show any statistically significant association with ORR or with PFS and OS (Table S1) . After a median (IQR) drug exposure of 2.2 (1.9-2.9) months treatment-related AEs occurred in 19 patients (67.8%), and consisted of Grade 3 skin toxicity in only three cases (10.7%, Table 3 and Fig. S2A,B) .
Post-Dacomitinib Follow-Up
The flow chart of administered treatments after dacomitinib discontinuation is shown in Fig. S3 . In all, 18 patients underwent lymphadenectomy, none of them achieved a pathological complete response, but fibrosis and necrosis were found in >90% of the residual tissue in one case. Four patients with enlarged, PET-positive, pelvic lymph nodes were pathologically down-staged to inguinal lymph node involvement. Only one patient received adjuvant chemotherapy, whilst chemotherapy was administered at relapse in 12 patients. Of them, only one partial response was obtained.
Results of Translational Analyses
In all, 25 patients had their tumours fully analysed. Of them, 19 had pre-dacomitinib lymph node biopsies analysed, whilst tissue from post-dacomitinib LND was used in six cases. Seven patients had matched pre-and post-dacomitinib tumour samples analysed. Only two patients had a HR-HPVpositive tumour, and EGFR amplification was confirmed in matched pre-post dacomitinib tumour samples in all four cases. No cases of ERBB2 amplification were found. The distribution of gene mutations occurring in >10% of cases is shown in Fig. S4 , and the OncoMap for the shared HotSpot and magic genes is provided in Fig. 3A . Mutation profile was largely consistent between pre-and post-treatment samples in seven patients analysed, except in particular for one case who was found to harbour missense mutations in ERBB2 gene (Fig. 3B) . Figure 3C provides the distribution of principal gene mutations in the response subgroups, among the 19 predacomitinib tumour samples: of note, TERT mutations were found in 60% of responders and in none of the nonresponders, and PI3K/mTOR pathway mutations [including phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PI3KCA), phosphatase and tensin homologue (PTEN), mTOR, TSC1 genes] were found in 42.9% of responders vs 8.3% of non-responders. The remaining genes were equally distributed between the two groups. Two exemplifying cases of responding patients are shown in Fig. S5A ,B.
Discussion
In the present proof-of-concept, phase 2 study, dacomitinib was endowed with clinical activity against metastatic PSCC. Although the ORR is lower than that reported with the use of neoadjuvant chemotherapy, it should be noted that our study enrolled a mixed population of patients with a generally more advanced PSCC, including cases with distant metastases. Therefore, attempts to make comparisons between studies can be pursued with only two prospective phase 2 studies that were close to the present study in their design: the first one is the Cancer Research UK (CRUK)/09/001 trial that assessed the activity of TPF chemotherapy, and reported 38.5% ORR in the 26 patients enrolled. The second study, sponsored by the EORTC, evaluated the cisplatin and irinotecan doublet, and an overall 30.8% ORR in 26 patients was obtained [5, 25] . The ORR of the above regimens is therefore consistent with that of dacomitinib. Additionally, if we look at the results that we achieved with dacomitinib in patients with locally advanced (lymph node only) disease, the PFS and OS estimates did approximate those obtained with the most active combined regimens including TIP, TPF, and a few others. Interestingly, the median OS obtained with the use of TIP chemotherapy was 17 months, and in our present study a median OS of 20 months was seen in the 20 patients with regional lymph node involvement. Obviously, such a comparison suffers from huge limitations, mainly attributable to the small sample size in both studies and patient heterogeneity. Also, the follow-up duration of our present study is shorter that that reported in the TIP study (19.8 vs 34 months), and the latter included patients of non-Caucasian ethnicity, who may not be fully comparable with men usually enrolled in European studies. Of course, the population of locally advanced patients included in Her-Uro-01 study was characterised by distinct poor prognostic features: 11 patients in fact (39.3%) had already received a radical LND in their past, thus being very close to visceral metastatic patients. Additionally, 14 (50%) presented with pelvic lymph node involvement and 17 (60.7%) had a bilateral inguinal lymph node extent.
OS results were minimally influenced by the administration of subsequent chemotherapy, because only one patient received adjuvant TPF chemotherapy after LND and the few patients who received second-line chemotherapy did not benefit with appreciable responses. These findings support the hypothesis that the first-line/preoperative window is probably the most suitable platform to test the activity of new drugs in PSCC, and limited activity can be obtained beyond the firstline with any treatment. Although the evaluation of the pathological response to dacomitinib may be more challenging compared to chemotherapy, it was poor in our present study. In fact, we did not observe any pathological complete responses, compared to an average of 10-12% pathological complete response achieved with the most active chemotherapy regimens [8] . This result should favour the design of new studies of dacomitinib combined with chemotherapy. However, there were~35% of patients who benefited with long-term remission from dacomitinib alone followed by surgery, despite the evidence of residual foci of viable cancer in lymph nodes on histological examination. In the pre-surgical window, the possibility of administering a short course of an active and well-tolerated single-agent therapy definitely represents a major improvement in the field, and potentially an opportunity to set new therapeutic standards. Although the efficacy results need validation in larger patient cohorts, preferably within multicentric studies, the issue of tolerability of treatment is clearly in favour of dacomitinib vs chemotherapy. Side-effects reported are significant with combined chemotherapy regimens: e.g., with TPF chemotherapy, 65.5% of the patients had Grade 3-4 AEs in the CRUK/09/001 trial, and AEs were also significant with the same regimen in other studies, including our Institutional experience [5] [6] [7] . Grade 3 AEs consisted of three cases of skin toxicity only, and of course the prophylactic use of topical treatment, as well as oral antibiotics, substantially lowered the impact of cutaneous side-effects, as previously reported [26] . Possible limitations to the use of short neoadjuvant courses lie in the limited data on post-surgical complications, although we did not observe any post-surgical AEs that may be associated with dacomitinib therapy (data not reported). Also, the total drug exposure was limited (the median was 2.2 months), and consequently responding patients might have benefited from a longer dacomitinib treatment course.
Looking at the eight patients with visceral metastatic disease, an improvement in PFS and OS may be hypothesised compared to chemotherapy: 6-month PFS was 16.7% in our present study compared to 8.5% with chemotherapy, and 12-month OS was 35% vs the reported 9.6% with chemotherapy from the literature [9] . Also, one partial response was obtained in a patient with visceral metastases.
Finally, results from the translational analyses added information on the biology underlying PSCC, and on putative mechanisms of response to anti-HER therapy [27] [28] [29] . NGS analyses were primarily aimed at evaluating the HER pathway gene alterations. In a background of multiple mutations of potentially druggable genes, these analyses, added to the evaluation of EGFR and ERBB2 amplification, did provide early evidence that response to pan-HER TKI may depend on downstream effector alterations of HER signalling. In particular, PI3K/mTOR pathway gene alterations may be associated with dacomitinib activity. The association of TERT gene alterations, already reported in PSCC [27] , needs additional studies using comprehensive genomic analyses to evaluate possible interplay with anti-HER activity.
In conclusion, at present the use of dacomitinib provided the most promising results in the field of anti-HER targeting of advanced PSCC. Single-agent dacomitinib may be proposed as a therapeutic option whenever triple combined regimens cannot be safely administered. Most importantly, subsequent studies will have to evaluate longer treatment duration, as well as the association of dacomitinib with chemotherapy or radiotherapy to improve outcomes. A clinical trial of afatinib, another pan-HER TKI, is currently recruiting patients as second-line therapy in the USA (NCT02541903). Combined results from these studies may elucidate the role of HER-targeting throughout the treatment course of patients with PSCC.
Funding
Dacomitinib (PF-00299804) treatment was supplied by Pfizer Inc., New York, USA. Translational analyses and study conduct were funded by the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Genes that are included in the two custom panels currently in use at the Fondazione IRCCS Istituto Nazionale dei Tumori, through the Ion Torrent Personal Genome Machine TM platform (Life Technologies, Carlsbad, CA, USA). Figure S2 . Incidence of AEs in the total safety population (A, N = 28), and pictures showing typical Grade 3 acneiform rash associated with dacomitinib treatment (B). Figure S3 . Flow chart of the post-dacomitinib follow-up. Figure S4 . Distribution of gene mutations occurring with a frequency of >10%. Figure S5 . Exemplifying responding case number 1 (A): patient presenting with lymph node relapse after bilateral inguinal LND (CT scan and 18 FDG-PET/CT scans are provided). He was found to harbour mutations in Wilms tumour 1 (WT1), IGF2R, and TERT genes, showed a near complete response after 8 weeks of dacomitinib, and received right inguinal-pelvic LND. On the surgical specimen, an overlapping mutation profile was found in the remaining tumour. Exemplifying case number 2 (B): patient presenting with enlarged inguinal and pelvic lymph nodes (CT scan and 18 FDG-PET/CT scans are provided), achieving a partial response after 8 weeks of dacomitinib. Also in this case, a unilateral inguinal-pelvic LND was performed 8 weeks after dacomitinib initiation (no translational data have been collected on the residual tumour in this case). Both patients had no evident disease at the time of last follow-up. Table S1 . Univariable Cox regression analyses on PFS and OS endpoints. 
